In this issue:
Belzutifan/cabozantinib combo may be a post-immunotherapy option for RCC
JAVELIN Renal 101: avelumab + axitinib prolongs PFS vs sunitinib in RCC
Low response rate to frontline avelumab/axitinib in urothelial cancer
ICI ± VEGF targeted therapy in metastatic translocation RCC
Savolitinib + durvalumab has activity in MET-driven papillary RCC
When can diagnostic ureteroscopy be safely omitted in suspected UTUC?
2023 update to EAU/ASCO guidelines on penile cancer
CPS is a biomarker of response to nivolumab in urothelial cancer
Detectable ctDNA prognostic for survival in patients with germ cell tumours
FDG-PET/CT may improve preoperative staging in NMIBC
Please login below to download this issue (PDF)